Melanoma Clinical Trials in Tennessee

Showing 161-180 of 285 trials

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Head and Neck CancerMelanomaHPV-Related Malignancy+5 more

Repertoire Immune Medicines22 participantsStarted May 2021

Scottsdale, Arizona, United States • Ann Arbor, Michigan, United States • Nashville, Tennessee, United States

COMPLETEDPhase 129 miles

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung Cancer+1 more

Eli Lilly and Company210 participantsStarted Sep 2016

Washington D.C., District of Columbia, United States • Sarasota, Florida, United States • Boston, Massachusetts, United States +10 more locations

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Melanoma Trials in Other Cities

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Safety Study of MGA271 in Refractory Cancer

Safety Study of SEA-CD40 in Cancer Patients

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Engaging Moms on Teen Indoor Tanning Through Social Media

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

A Study of PLX2853 in Advanced Malignancies.

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Tennessee